Provided by Tiger Trade Technology Pte. Ltd.

GRI BIO INC

0.4193
-0.0593-12.39%
Post-market: 0.4106-0.0087-2.07%19:43 EST
Volume:1.20M
Turnover:521.06K
Market Cap:2.46M
PE:-0.03
High:0.4720
Open:0.4695
Low:0.3950
Close:0.4786
52wk High:15.64
52wk Low:0.3950
Shares:5.87M
Float Shares:5.87M
Volume Ratio:0.29
T/O Rate:20.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.9488
EPS(LYR):-55.2058
ROE:-397.84%
ROA:-137.52%
PB:1.24
PE(LYR):-0.01

Loading ...

Company Profile

Company Name:
GRI BIO INC
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
4
Office Location:
2223 Avenida de la Playa,Suite 208,La Jolla,California,United States
Zip Code:
92037
Fax:
- -
Introduction:
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.

Directors

Name
Position
W. Marc Hertz
Chief Executive Officer and Director and President
Camilla V. Simpson
Independent Director
David Szekeres
Chair of the Board and Independent Director
Roelof Rongen
Independent Director
David Baker
Director

Shareholders

Name
Position
W. Marc Hertz
Chief Executive Officer and Director and President
Leanne Kelly
Chief Financial Officer
Albert Agro
Chief Medical Officer
Vipin Kumar Chaturvedi
Chief Scientific Officer